Results 111 to 120 of about 46,312 (227)

Anticoagulation management for cardiopulmonary bypass using TEG® 6 s in a patient receiving both heparin and dabigatran

JA Clinical Reports
Background It is difficult to evaluate adequate dose of heparin for cardiopulmonary bypass (CPB) by activated clotting time (ACT) in a patient receiving both heparin and dabigatran because dabigatran can also prolong ACT.
Yu Kawada, Nobuyuki Katori, Keiko Kaji, Shoko Fujioka, Tomoki Yamaguchi   +4 more
doaj   +1 more source

The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit–risk ratio

Therapeutic Advances in Neurological Disorders, 2015
Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of
Apostolos Safouris, Nikos Triantafyllou, John Parissis, Georgios Tsivgoulis   +3 more
doaj   +1 more source

Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation: An Evidence Based Case Report

Majalah Kardiologi Indonesia, 2013
Background. Atrial fibrillation (AF) increases the risk of having stroke as high as five fold. Anticoagulant administration such as vitamin K antagonist has been used regularly to reduce the occurence of stroke.
Alvin Nursalim, Yoga Yuniadi
doaj   +1 more source

Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice. [PDF]

, 2018
© 2018 Vimalesvaran et al. This work is published and licensed by Dove Medical Press Limited.Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and it leads to significant morbidity and mortality, predominantly from ischemic stroke.
Dockrill, Seth J, Gorog, Diana, Vimalesvaran, Kavitha   +2 more
core   +3 more sources

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2018
Background Frailty predicts poorer outcomes and decreased anticoagulation use in patients with nonvalvular atrial fibrillation. We sought to assess the effectiveness and safety of apixaban, dabigatran and rivaroxaban versus warfarin in frail nonvalvular ...
B. Martinez, Nitesh A. Sood, T. Bunz, C. Coleman   +3 more
semanticscholar   +1 more source

Dabigatran must be used carefully: literature review and recommendations for management of adverse events

Drug Design, Development and Therapy, 2019
Atrial fibrillation increases the risk of stroke and death. The vitamin-K antagonist warfarin is recommended for patients with atrial fibrillation, but vitamin-K antagonists are cumbersome to use.
Shan Lin, Yan Wang, Lei Zhang, Wei-Yu Guan   +3 more
semanticscholar   +1 more source

Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. [PDF]

, 2019
IntroductionPatient-reported outcomes (PROs) and satisfaction endpoints are increasingly important in clinical trials and may be associated with treatment adherence.
Becker, Richard C, Berkowitz, Scott D, Breithardt, Guenter, Fox, Keith AA, Hacke, Werner, Halperin, Jonathan L, Hankey, Graeme J, Hellkamp, Anne S, Mahaffey, Kenneth W, Nessel, Christopher C, Patel, Manesh R, Piccini, Jonathan P, Rodriguez, Fatima, Singer, Daniel E, Ungar, Leo   +14 more
core   +1 more source

Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry.

American Journal of Cardiology, 2019
Prospective studies evaluating persistence to nonvitamin K antagonist oral anticoagulants in patients with atrial fibrillation are needed to improve our understanding of drug discontinuation.
M. Paquette, L. Franca, C. Teutsch, H. Diener, Shihai Lu, S. Dubner, Changsheng Ma, K. Rothman, K. Zint, J. Halperin, B. Olshansky, M. Huisman, G. Lip, R. Nieuwlaat   +13 more
semanticscholar   +1 more source

Dabigatran versus warfarin in patients with atrial fibrillation.

New England Journal of Medicine, 2009
S. Connolly, M. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P. Reilly, E. Themeles, Jeanne Varrone, Susan Wang, M. Alings, D. Xavier, Jun Zhu, R. Diaz, B. Lewis, H. Darius, H. Diener, C. Joyner, L. Wallentin   +19 more
semanticscholar   +1 more source

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

New England Journal of Medicine, 2017
C. Cannon, Deepak L. Bhatt, J. Oldgren, G. Lip, S. Ellis, Takeshi Kimura, M. Maeng, B. Merkely, U. Zeymer, S. Gropper, M. Nordaby, E. Kleine, Ruth Harper, Jenny Manassie, J. Januzzi, J. T. ten Berg, G. Steg, S. Hohnloser   +17 more
semanticscholar   +1 more source